• 我要登录|
  • 免费注册
    |
  • 我的丁香通
    • 企业机构:
    • 成为企业机构
    • 个人用户:
    • 个人中心
  • 移动端
    移动端
丁香通 logo丁香实验_LOGO
搜实验

    大家都在搜

      大家都在搜

        0 人通过求购买到了急需的产品
        免费发布求购
        发布求购
        点赞
        收藏
        wx-share
        分享

        Cyclooxygenase 2-Dependent Regulation of Antitumor Immunity in Lung Cancer

        互联网

        723
        Lung cancer is the leading cause of cancer death in the United States (1 ). Many tumors, including lung cancer, have the capacity to promote immune tolerance and escape host immune surveillance (2 ). Tumors utilize numerous pathways to inhibit immune responses including the elaboration of immune inhibitory cytokines. In addition to direct secretion of immunosuppressive cytokines, lung cancer cells may induce host cells to release immune inhibitors (3 7 ). We have reported previously that human lung cancer cell-derived prostaglandin E2 (PGE2) can orchestrate an imbalance in the production of interleukins (IL)-10 and -12 in lymphocytes and macrophages (5 ). IL-10 and -12 are critical regulatory elements of cell-mediated antitumor immunity. While IL-10 inhibits important aspects of cell-mediated immunity, IL-12 induces type 1 cytokine production and effective antitumor cell-mediated responses (8 12 ). IL-10 overproduction at the tumor site has been implicated in tumor-mediated immune suppression (13 ,14 ). In contrast, IL-12 is critical for effective antitumor immunity (15 ,16 ). In both tumor models and patients, the tumor-bearing state induces lymphocyte and macrophage IL-10 but inhibits macrophage IL-12 production (5 ,6 ,17 19 ). Because PGE2 appears to be pivotal in the reciprocal regulation of IL-10 and IL-12 (20 ,21 ), we have sought to determine the pathways responsible for its high-level production at the tumor site.
        ad image
        提问
        扫一扫
        丁香实验小程序二维码
        实验小助手
        丁香实验公众号二维码
        扫码领资料
        反馈
        TOP
        打开小程序